Napo Pharmaceuticals

United States
Wrightstown, Wisconsin, United States, 94107

Company profile

Napo Pharmaceuticals company profile

Napo Pharmaceuticals, Inc. develops and commercializes proprietary pharmaceuticals for international markets. It offers Crofelemer for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS; and NP-500, a product for insulin-resistant diseases. The company also provides CRO-IBS for diarrhea-predominant IBS; CRO-HIV for AIDS-related diarrhea; CRO-ID for acute infectious diarrhea; and CRO-PED for pediatric diarrhea. It offers its products for D-IBS, HIV, acute-cholera, and pediatric markets. The company was founded in 2001 and is based in San Francisco, California. It has a subsidiary location in Mumbai, India.

Business identity

Contact email
[email protected]
Phone number
+114153718300
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2001-01-01, Year

Headquarters

Postal code
94107
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
7
Total equity funding
$17.5M
Last funding
Series Unknown / $7.5M / 2023-02-09
Last equity funding
Series Unknown / $7.5M
Investors
3
Lead investors
1
Founders
1
Articles
91
Exited on
2017-03-31

Founders and investors

Founders

Lisa Conte

Lead investors

Kingdon Capital

Investors

Jaguar HealthKingdon CapitalSPRIM Ventures